References
Golomb BA, Kopersli S, Evans M. Statins and muscle adverse events: a complementary perspective [letter]. Drug Saf 2010; 33(9): 803
Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171–87
Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–90
Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286
Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373–418
Acknowledgements
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giannoglou, G.D., Koskinas, K.C. & Chatzizisis, Y.S. The Authors’ Reply. Drug-Safety 33, 803–804 (2010). https://doi.org/10.2165/11538830-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11538830-000000000-00000